PER 2.50% 8.2¢ percheron therapeutics limited

Open House 09/SEP/2024, page-33

  1. 13,256 Posts.
    lightbulb Created with Sketch. 1408
    I’m confused
    Our DMD trial is in Europe
    So we need the ok from the European authorities.
    To commercialise our drug in Europe

    now

    wer’e all talking about the FDA

    my understanding is if the DMD trial is Stella
    we go to the FDA with our Tox study
    and possibly we get commercialisation in the US

    Can anyone set me straight ?

    in other words
    if we get the green light in Europe
    that’s a Coy maker
    remembering Sarepta has none of its 4 drugs approv d in Europe.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.2¢
Change
0.002(2.50%)
Mkt cap ! $73.92M
Open High Low Value Volume
8.2¢ 8.7¢ 7.9¢ $122.1K 1.460M

Buyers (Bids)

No. Vol. Price($)
1 50000 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.6¢ 6250 1
View Market Depth
Last trade - 15.59pm 10/09/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.